Gene Garrard Olinger, Jr. received his Ph.D. from Rush University Medical Center in Chicago, IL in 2001. Currently, Dr. Olinger is the principal advisor science for MRI Global Inc.
Dr. Olinger holds a Masters in Business Administration from Mount Saint Mary’s University in Emmittsburg, MD, has completed executive training at Massachusetts Institute of Technology, Boston, MA, and completed Department of Defense Acquisition and Executive Leadership training. He is the recipient of the Achievement Medal for Civilian Service Medals in 2005 and 2010, Commander’s Award for Civilian Service in 2013, and the NIH Director Award in 2015 for his efforts assisting with the Ebola outbreak in Western Africa. Dr. Olinger is active in multiple STEM programs and mentors high school, undergraduate graduate students and post-doctoral fellows.
- Associate Director for Maximum Containment Training, NEIDL, National Emerging Infectious Disease Lab, Boston University School of Medicine
- Rush University, PhD
- Mount St. Mary's University, MBA
- Old Dominion University, BS
- Published on 3/22/2018
Postnikova E, Cong Y, DeWald LE, Dyall J, Yu S, Hart BJ, Zhou H, Gross R, Logue J, Cai Y, Deiuliis N, Michelotti J, Honko AN, Bennett RS, Holbrook MR, Olinger GG, Hensley LE, Jahrling PB. Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS One. 2018; 13(3):e0194880. PMID: 29566079.
- Published on 2/23/2018
Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Sarro YDS, Pettitt J, Stavale EJ, Fallah M, Olinger GG, Bolay FK, Hensley LE. Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. J Virol Methods. 2018 05; 255:84-90. PMID: 29481881.
- Published on 12/1/2017
Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Hensley LE, Frieman MB, Jahrling PB. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs. 2017 Dec; 77(18):1935-1966. PMID: 29143192.
- Published on 7/19/2017
Honko AN, Johnson JC, Marchand JS, Huzella L, Adams RD, Oberlander N, Torzewski LM, Bennett RS, Hensley LE, Jahrling PB, Olinger GG. High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. Sci Rep. 2017 Jul 19; 7(1):5886. PMID: 28725019.
- Published on 6/14/2017
Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W. Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice. J Virol. 2017 Jun 14. PMID: 28615211.
- Published on 5/1/2017
Dyall J, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Freeburger D, Michelotti J, Honko AN, DeWald LE, Bennett RS, Olinger GG, Jahrling PB, Hensley LE. Interferon-ß and Interferon-? Are Weak Inhibitors of Ebola Virus in Cell-Based Assays. J Infect Dis. 2017 May 01; 215(9):1416-1420. PMID: 28368541.
- Published on 4/12/2017
Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG, White JM. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl Trop Dis. 2017 Apr; 11(4):e0005540. PMID: 28403145.
- Published on 1/1/2017
Bennett RS, Huzella LM, Jahrling PB, Bollinger L, Olinger GG, Hensley LE. Nonhuman Primate Models of Ebola Virus Disease. Curr Top Microbiol Immunol. 2017; 411:171-193. PMID: 28643203.
- Published on 1/1/2017
Connor J, Kobinger G, Olinger G. Therapeutics Against Filovirus Infection. Curr Top Microbiol Immunol. 2017; 411:263-290. PMID: 28653190.
- Published on 11/30/2016
Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG, Bennett RS, Holbrook MR, Hensley LE, Jahrling PB. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. PLoS One. 2016; 11(11):e0166318. PMID: 27902714.
View 70 more publications: View full profile at BUMC